STVN vs WST vs GTLS vs BDX vs AVTR

For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.

2% revenue growth year-over-year, versus -3. 4% for Avantor, Inc. (AVTR). Becton, Dickinson and Company (BDX) offers the better valuation at 25. 6x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Stevanato Group S. p. A. (STVN) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 25.

6x versus Chart Industries, Inc. at 628. 6x. On forward P/E, Avantor, Inc. is actually cheaper at 10. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus West Pharmaceutical Services, Inc. 's 4. 57x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Chart Industries, Inc.

(GTLS) delivered a total return of +40. 6%, compared to -72. 7% for Avantor, Inc. (AVTR). Over 10 years, the gap is even starker: GTLS returned +772. 7% versus AVTR's -42. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Chart Industries, Inc.

(GTLS) is the lower-risk stock at 0. 49β versus Avantor, Inc. 's 1. 55β — meaning AVTR is approximately 215% more volatile than GTLS relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 111% for Chart Industries, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.

2% versus -3. 4% for Avantor, Inc. (AVTR). On earnings-per-share growth, the picture is similar: Stevanato Group S. p. A. grew EPS 14. 0% year-over-year, compared to -175. 0% for Avantor, Inc.. Over a 3-year CAGR, GTLS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus -8. 1% for Avantor, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus -3. 8% for AVTR. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus West Pharmaceutical Services, Inc. 's 4. 57x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Avantor, Inc. (AVTR) trades at 10. 6x forward P/E versus 37. 8x for West Pharmaceutical Services, Inc. — 27. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for STVN: 34. 4% to $24. 50.

In this comparison, BDX (2.

8% yield), STVN (0. 3% yield), GTLS (0. 3% yield), WST (0. 3% yield) pay a dividend. AVTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Chart Industries, Inc.

(GTLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 49), +772. 7% 10Y return). Avantor, Inc. (AVTR) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GTLS: +772. 7%, AVTR: -42. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (STVN (Healthcare) and WST (Healthcare) and GTLS (Industrials) and BDX (Healthcare) and AVTR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

BDX pays a dividend while STVN, WST, GTLS, AVTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.